Loading
A phase 2 trial of Venetoclax in multiple myeloma, run by Oncotherapeutics, now recruiting.
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06115135 by Oncotherapeutics, with 39 participants planned, started 2024-06-20 and due to reach its primary completion in 2026-04-30. Interventions recorded: Venetoclax. Conditions listed: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BCL-2 inhibitors, Venetoclax, Multiple myeloma, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/